Shin Nippon Biomedical Laboratories (2395) Stock Overview
A contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
2395 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shin Nippon Biomedical Laboratories, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,602.00 |
| 52 Week High | JP¥2,005.00 |
| 52 Week Low | JP¥1,142.00 |
| Beta | -0.45 |
| 1 Month Change | -12.84% |
| 3 Month Change | 3.09% |
| 1 Year Change | -4.30% |
| 3 Year Change | -29.89% |
| 5 Year Change | 120.36% |
| Change since IPO | -26.85% |
Recent News & Updates
Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00
Dec 14
Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00
Nov 29Earnings Tell The Story For Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) As Its Stock Soars 26%
Nov 28Recent updates
Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00
Dec 14Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00
Nov 29Earnings Tell The Story For Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) As Its Stock Soars 26%
Nov 28Shin Nippon Biomedical Laboratories' (TSE:2395) Earnings Seem To Be Promising
Nov 14Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Aug 18Shin Nippon Biomedical Laboratories, Ltd. Recorded A 6.7% Miss On Revenue: Analysts Are Revisiting Their Models
Aug 08Shin Nippon Biomedical Laboratories (TSE:2395) Has Announced A Dividend Of ¥20.00
Jul 23Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥20.00
Jul 09There May Be Some Bright Spots In Shin Nippon Biomedical Laboratories' (TSE:2395) Earnings
May 15Investors Continue Waiting On Sidelines For Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395)
Apr 28Estimating The Intrinsic Value Of Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395)
Apr 04Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00
Mar 05Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00
Feb 10Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00
Jan 10Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00
Dec 19Shin Nippon Biomedical Laboratories (TSE:2395) Is Paying Out A Dividend Of ¥30.00
Dec 02What Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) 25% Share Price Gain Is Not Telling You
Nov 25Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Sep 19Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts
Aug 09Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding
Aug 06Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 26Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 12Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 21Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 10Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00
Mar 12Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00
Feb 27Shareholder Returns
| 2395 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -1.4% | 1.7% | 0.7% |
| 1Y | -4.3% | -1.6% | 32.7% |
Return vs Industry: 2395 underperformed the JP Life Sciences industry which returned -1.6% over the past year.
Return vs Market: 2395 underperformed the JP Market which returned 32.7% over the past year.
Price Volatility
| 2395 volatility | |
|---|---|
| 2395 Average Weekly Movement | 4.8% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 8.0% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 2395 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 2395's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 1,531 | Ryoichi Nagata | www.snbl.co.jp |
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation delivery technology, discovery of future seeds, and business promotion activities; and development of artificial seed production for Japanese eels.
Shin Nippon Biomedical Laboratories, Ltd. Fundamentals Summary
| 2395 fundamental statistics | |
|---|---|
| Market cap | JP¥66.69b |
| Earnings (TTM) | JP¥4.65b |
| Revenue (TTM) | JP¥34.67b |
Is 2395 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2395 income statement (TTM) | |
|---|---|
| Revenue | JP¥34.67b |
| Cost of Revenue | JP¥17.56b |
| Gross Profit | JP¥17.11b |
| Other Expenses | JP¥12.46b |
| Earnings | JP¥4.65b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 06, 2026
| Earnings per share (EPS) | 111.79 |
| Gross Margin | 49.36% |
| Net Profit Margin | 13.42% |
| Debt/Equity Ratio | 98.5% |
How did 2395 perform over the long term?
See historical performance and comparisonDividends
Does 2395 pay a reliable dividends?
See 2395 dividend history and benchmarks| Shin Nippon Biomedical Laboratories dividend dates | |
|---|---|
| Ex Dividend Date | Mar 30 2026 |
| Dividend Pay Date | Jun 30 2026 |
| Days until Ex dividend | 67 days |
| Days until Dividend pay date | 159 days |
Does 2395 pay a reliable dividends?
See 2395 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/21 19:07 |
| End of Day Share Price | 2026/01/21 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shin Nippon Biomedical Laboratories, Ltd. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuki Tsukamoto | BofA Global Research |
| Akitada Iwasa | Daiwa Securities Co. Ltd. |
| Stephen Barker | Jefferies LLC |